Haemonetics Corporation (HAE) Investor Relations Documents
Haemonetics Corporation (HAE) investor relations documents from the company's IR site: 1 presentation, 22 press releases; latest deck 2026-06-05. Read in-app with summaries. First-party data.
Reportable Segment Changes Presentation — Haemonetics Corporation is restructuring its reportable segments from three to two, effective Q1 FY27, to align with its management structure.
Investor relations documents — source: company IR site| Published | Type | Document |
|---|
| 2026-08-06 | Press release | Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website |
| 2026-08-03 | Press release | New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with |
| 2026-07-28 | Press release | Martin Madaus Elected to Haemonetics Board of Directors |
| 2026-07-08 | Press release | Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026July 8, 2026Read more |
| 2026-06-05 | Presentation | Reportable Segment Changes Presentation |
| 2026-06-05 | Press release | Haemonetics Updates Financial Reporting SegmentsJune 5, 2026Read more |
| 2026-06-02 | Press release | Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceJune 2, 2026Read more |
| 2026-05-07 | Press release | Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations WebsiteMa |
| 2026-05-05 | Press release | Haemonetics to Present at Bank of America 2026 Healthcare ConferenceMay 5, 2026Read more |
| 2026-04-24 | Press release | New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Pro |
| 2026-04-01 | Press release | Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026April 1, 2026Read more |
| 2026-03-30 | Press release | Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure SystemMarch 30, 2 |
| 2026-02-23 | Press release | Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS TechnologyFebruary 23, 20 |
| 2026-02-20 | Press release | Haemonetics to Present at Raymond James 47th Annual Institutional Investors ConferenceFebruary 20, 2026Read more |
| 2026-01-09 | Press release | Haemonetics Acquires Vivasure Medical LimitedJanuary 9, 2026Read more |
| 2025-02-06 | Press release | 3rd Quarter FY25 Earnings Release |
| 2025-02-06 | Press release | Read more |
| 2025-01-08 | Press release | Read more |
| 2024-08-08 | Press release | 1st Quarter FY25 Earnings Release |
| 2024-08-08 | Press release | Read more |
| 2024-07-08 | Press release | Read more |
| Press release | Read more |
| Press release | Read more |
HAE overview · HAE earnings · HAE financials · HAE KPIs · HAE ownership · HAE peers · HAE filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.